Inventor · disambiguated record
David Rosen
Also filed as: ROSEN DAVID · ROSEN DAVID B
7 granted patents·4 pending applications·11 citations·filing 2013–2022
79Inventor score
Top patents by PatentIndex Score
11 records- 0187US10030034B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2016·Granted Jul 24, 2018·5 cites·12 claims
- 0286US11879001B2Conjugate comprising an IL-2 moietyASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2022·Granted Jan 23, 2024·2 cites·30 claims
- 0385US9266874B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2013·Granted Feb 23, 2016·2 cites·9 claims
- 0484US10604533B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2018·Granted Mar 31, 2020·1 cites·15 claims
- 0583US11186593B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2020·Granted Nov 30, 2021·1 cites·19 claims
- 0676US11773110B2Heterocycle amines and uses thereofLIGAND PHARM INC·Filed 2021·Granted Oct 3, 2023·0 cites·11 claims
- 0757US12428461B2Treating cancer with a conjugate comprising an IL-2 moietyASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2021·Granted Sep 30, 2025·0 cites·26 claims
- 0851US2023340055A1Glycosylated il-2 proteins and uses thereofASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2021·Application pending·0 cites
- 0945US2022054476A1Sustained local drug levels for innate immune agonistsASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1045US2022054478A1Minimization of systemic inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
- 1145US2022054477A1Induction of sustained local inflammationASCENDIS PHARMA ONCOLOGY DIV A/S·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Rosen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →